Moderna Leads Race for Combined Flu/COVID Vaccine, Aiming for 2025 Launch

Vaccine makers like Moderna, Pfizer, and Novavax are racing to develop a single vaccine that protects against both flu and COVID-19.

Moderna is starting phase 3 trials for its combined vaccine and aims to launch it in 2025, potentially putting it ahead of rivals.

Pfizer also has a combined vaccine in early trials but hasn't released much data yet, so Moderna may have the upper hand currently.

A successful combined flu/COVID vaccine could be a billion-dollar recurring revenue source if it attracts the 50% of Americans who get annual flu shots.

Even if Moderna doesn't launch first, the global demand for a combined vaccine means there's room for multiple successful products from Moderna, Pfizer, and others.